DOI : 10.1055/s-00034925

Hämostaseologie

Issue S 01 · Volume 39 · February 2019 DOI: 10.1055/s-009-42463


63rd Annual Meeting of the Society of Thrombosis and Haemostasis Research
Berlin, Germany, 27.02 – 02.03.2019

Science meets clinical practice


P06-1/SY06-2-AB
Kremer, J.A. Hovinga; Scully, M.; Cataland, S.; Peyvandi, F.; Coppo, P.; Knoebl, P.; Metjian, A.; de la Rubia, J.; Pavenski, K.; Minkue, J.; Sousa, R.; Callewaert, F.; de Winter, H.; the HERCULES investigators: Safety Results Normalized to Time of Exposure during the Phase 3 HERCULES Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura
P06-3
Müller, J.; Gasper, S.; Shahidi-Hamedani, N.; Rühl, H.; Oldenburg, J.; Pötzsch, B.: Development and Validation of a Novel Flow Cytometric Assay for Quantification of Plasma ADAMTS-13 Activity (AD13a-FCA)
P06-5
Cataland, S.; Scully, M.; Peyvandi, F.; Coppo, P.; Knoebl, P.; Kremer, J.A. Hovinga; Metjian, A.; de la Rubia, J.; Pavenski, K.; Minkue, J.; Sousa, R.; Callewaert, F.; de Winter, H.; the HERCULES investigators: Risk Factors and Manageability of the Mucocutaneous Bleeding Profile Observed in aTTP Patients Treated with Caplacizumab during the Phase III HERCULES Study